Vyleesi Cost in Massachusetts 2026: Cash Price, Insurance, Medicaid, and Compounding Options

What Is Vyleesi (Bremelanotide) and Why Does Cost Vary So Much in Massachusetts?

Vyleesi is the brand name for bremelanotide, a melanocortin receptor agonist the FDA approved on June 21, 2019, for treating hypoactive sexual desire disorder (HSDD) in premenopausal women. It does not work like a hormone. Instead, it binds MC1R and MC4R receptors in the central nervous system to modulate the dopamine and serotonin pathways linked to sexual desire. Patients self-administer a single 1.75 mg subcutaneous injection from a disposable auto-injector roughly 45 minutes before anticipated sexual activity, with no more than one dose in 24 hours and no more than approximately eight doses per month.

Cost varies in Massachusetts for a straightforward reason: the drug is available through at least three distinct channels, each priced differently. The manufacturer, Palatin Technologies, sets a list price near $1,200 per month for brand Vyleesi. Commercial insurers and Medicaid negotiate their own rates, sometimes dramatically lower. And licensed 503A compounding pharmacies in Massachusetts may prepare patient-specific bremelanotide formulations that cost closer to $140 per month. The gap between those two endpoints, roughly $1,060, is large enough to change whether treatment is financially realistic for many patients.

The RECONNECT trial (N=1,267, published in Obstetrics and Gynecology in 2019) established the clinical evidence base that led to FDA approval. RECONNECT found statistically significant improvements in the number of satisfying sexual events and in desire scores on the Female Sexual Function Index compared to placebo, giving payers a documented clinical rationale to cover the drug. That published evidence is also what 503A compounding pharmacies rely on when pharmacists prepare individualized doses.

The 2026 Brand-Name List Price: What $1,200 Per Month Actually Means

The manufacturer's wholesale acquisition cost for Vyleesi sits at approximately $1,200 per monthly supply in 2026. That figure assumes a patient uses the drug roughly four to eight times per month, because each auto-injector is single-use and one carton typically contains four injectors.

What patients actually pay at the pharmacy depends on three things: whether they have insurance that covers Vyleesi, whether they qualify for the Palatin Technologies co-pay assistance program, and whether their pharmacy has negotiated a discount. Without any of those advantages, a Massachusetts resident paying cash at a retail pharmacy should expect a bill near the $1,200 list price.

For comparison, flibanserin (Addyi), the other FDA-approved HSDD treatment, also carries a list price above $800 per month. Neither drug has a lower-cost generic available in the United States. That reality pushes many prescribers and patients toward the compounding route when insurance coverage is denied or unavailable.

MassHealth Medicaid Coverage for Vyleesi in Massachusetts

MassHealth covers bremelanotide for eligible premenopausal women with HSDD, but prior authorization (PA) is required. That is the key administrative step. Without an approved PA, MassHealth will not pay for the prescription and the patient will owe the full retail price.

To obtain PA approval through MassHealth, the prescribing clinician typically must document that the patient meets the DSM-5 criteria for HSDD, that the condition is not better explained by a comorbid mood disorder or medication side effect, and that alternative non-pharmacologic interventions have been considered. The MassHealth Drug List is updated quarterly; clinicians should confirm the current PA criteria before submitting a request, as tier placement and required clinical documentation can change between calendar years.

The American College of Obstetricians and Gynecologists (ACOG) has stated that HSDD "is a legitimate medical diagnosis with significant impact on quality of life," a position that strengthens the PA argument when a clinician submits supporting documentation. Once approved, MassHealth members pay their standard cost-sharing amount, which is often far below the list price.

Patients whose PA requests are denied have the right to file an appeal. Massachusetts law requires MassHealth to render an expedited appeal decision within 72 hours when the prescriber certifies that a delay would seriously jeopardize the patient's health.

Commercial Insurance Coverage in Massachusetts: Which Plans Cover Vyleesi?

Coverage varies considerably across commercial plans sold in Massachusetts. Major carriers including Blue Cross Blue Shield of Massachusetts, Harvard Pilgrim Health Care, and Tufts Health Plan maintain formularies that are updated annually, so tier placement for Vyleesi changes from year to year.

A practical pattern: many commercial plans in Massachusetts place Vyleesi on a non-preferred specialty tier, which means a PA is required and cost-sharing can be $100 to $400 per fill even after approval. Some plans exclude it outright under a "lifestyle drug" or "sexual dysfunction" exclusion, though those exclusions are increasingly challenged under mental health parity laws because HSDD is a recognized psychiatric diagnosis in DSM-5.

Patients should take three specific steps before giving up on commercial coverage. First, request the plan's formulary exception form and submit it with a letter of medical necessity from the prescriber. Second, ask the prescriber to document the functional impairment and relationship distress caused by HSDD, not just the diagnosis code. Third, check whether the plan's exclusion might violate Massachusetts mental health parity law (M.G.L. c. 176A, s. 8N), which requires parity between mental health and medical benefits.

The FDA label for Vyleesi explicitly identifies HSDD as the approved indication, and that language is useful to include verbatim in any coverage appeal letter.

The Palatin Technologies Savings Card: How It Works in Massachusetts

Palatin Technologies offers a co-pay assistance program for commercially insured patients. The program has historically allowed eligible patients to pay as little as $0 for the first prescription and reduced amounts for subsequent fills, subject to program caps.

Key eligibility rules: the savings card is available only to patients with commercial (private) insurance. It does not apply to patients whose primary coverage is a federal or state government program, including Medicare, Medicaid, or TRICARE. Massachusetts residents on MassHealth are therefore not eligible.

The program sets an annual cap on total savings per patient, which has been approximately $2 to 400 in recent program years. Once that cap is reached, the patient pays the plan's standard cost-share. Patients should enroll directly at Palatin's official Vyleesi savings program page and bring the card to their Massachusetts pharmacy at the time of dispensing.

Pharmacists can also run the savings card through the pharmacy's third-party processor. If the card is rejected, the most common reasons are that the patient's insurance was identified as a government plan or that the annual cap was already met.

Compounded Bremelanotide in Massachusetts: Legality, Cost, and What to Expect

Compounded bremelanotide is legal in Massachusetts when prepared by a licensed 503A compounding pharmacy for a patient-specific prescription. Section 503A of the Federal Food, Drug, and Cosmetic Act permits licensed pharmacists to compound drugs for individual patients upon receipt of a valid prescription from a licensed practitioner.

The cost advantage is substantial. Where brand Vyleesi runs approximately $1,200 per month, compounded bremelanotide from a Massachusetts-licensed 503A pharmacy typically costs around $140 per month in 2026. That price difference, roughly $1,060 per month, is the primary reason many Massachusetts prescribers and patients pursue the compounding route after commercial insurance denies coverage.

There are clinical and regulatory trade-offs to understand. Compounded drugs are not FDA-approved. The FDA has not evaluated the potency, purity, or sterility of any specific compounded bremelanotide preparation. The active pharmaceutical ingredient (API) used by the compounder must be obtained from an FDA-registered facility, but the finished compounded product does not go through the same pre-market review process as brand Vyleesi. That matters for subcutaneous injections in particular, because sterility failures can cause serious local or systemic infections.

Patients choosing compounded bremelanotide should verify that their Massachusetts pharmacy holds a current 503A license issued by the Massachusetts Board of Pharmacy, that the pharmacy uses API sourced from an FDA-registered supplier, and that the final product undergoes sterility and potency testing by an independent third-party laboratory. Ask for the certificate of analysis before accepting the first shipment.

The dose for compounded bremelanotide is typically 1.75 mg per injection, matching the approved brand dose, though some prescribers order slightly different concentrations depending on the patient's response. The RECONNECT trial data that supports Vyleesi's approval was based on the 1.75 mg dose, so deviating from that dose moves further from the published evidence base.

Compounded bremelanotide is not covered by MassHealth or most commercial insurance plans. Patients typically pay out of pocket. Some telehealth platforms that ship compounded formulations include a dispensing fee in the monthly subscription, so the all-in cost may be slightly above the pharmacy-only price.

Telehealth Prescribing of Vyleesi in Massachusetts: What the Rules Allow

Massachusetts permits telehealth prescribing of Vyleesi for HSDD, provided the prescribing clinician holds a valid Massachusetts medical or advanced practice nursing license and establishes an appropriate provider-patient relationship. The prescriber does not need to have seen the patient in person before writing a bremelanotide prescription, as long as the telehealth visit meets the Massachusetts Board of Registration in Medicine standards for establishing a provider-patient relationship.

Practically, a qualifying telehealth visit for bremelanotide involves a video or audio consultation during which the clinician takes a medical and sexual history, screens for contraindications (particularly cardiovascular disease, because bremelanotide causes a transient increase in blood pressure and decrease in heart rate), and confirms that the patient is premenopausal and meets HSDD diagnostic criteria.

Contraindications listed in the FDA-approved label include known cardiovascular disease. The label specifies that blood pressure and heart rate should be measured before prescribing, and clinicians conducting telehealth visits typically ask patients to self-report recent blood pressure readings or obtain them at a local pharmacy.

Several national telehealth platforms serve Massachusetts patients and offer monthly subscription models that include the clinical consultation fee, the compounded bremelanotide, and supplies. Costs at these platforms generally range from $120 to $200 per month, inclusive of the medication. That compares favorably with the $1,200 brand list price even before any insurance is applied.

Patients using telehealth for brand Vyleesi (rather than compounded) should confirm that the platform's prescribers can send the prescription to a Massachusetts retail pharmacy that participates in the Palatin savings card program.

Comparing All Cost Pathways: A Practical Summary for Massachusetts Patients in 2026

The most useful way to think about Vyleesi cost in Massachusetts is to map each cost pathway against a patient's insurance situation.

Commercially insured patients with a plan that covers Vyleesi should apply for PA, use the Palatin savings card to minimize co-pays, and appeal any denial with a documented letter of medical necessity. Out-of-pocket cost with the savings card active can drop to near $0 for the first fill.

MassHealth-enrolled patients should request PA through their prescriber. MassHealth covers the drug when PA is approved, and the patient's standard cost-sharing applies. The Palatin savings card does not apply to MassHealth patients.

Uninsured or cash-pay patients face the full $1,200 list price for brand Vyleesi unless they access a discount through GoodRx or similar platforms, which may reduce the retail price at some Massachusetts pharmacies by 10% to 30%. Compounded bremelanotide at approximately $140 per month represents the lowest-cost option for this group, assuming they accept the trade-offs described above.

Patients with insurance that excludes Vyleesi should pursue a formulary exception or appeal, simultaneously get a prescription for compounded bremelanotide as a backup, and clarify whether the exclusion might violate Massachusetts parity law before paying out of pocket indefinitely.

Clinical Efficacy Context: What the Evidence Shows

Cost is only worth paying if the drug works. The RECONNECT trial, published in Obstetrics and Gynecology in 2019, was a pair of randomized, double-blind, placebo-controlled phase 3 studies with a combined enrollment of N=1,267 premenopausal women diagnosed with HSDD. Patients receiving bremelanotide 1.75 mg showed statistically significant improvements in the number of satisfying sexual events per month and in the desire domain of the Female Sexual Function Index compared with patients receiving placebo (P<0.001 for desire score change in the primary analysis).

The most common adverse effects in RECONNECT were nausea (40.0% bremelanotide vs. 1.2% placebo), flushing (20.4% vs. 0.7%), and headache (11.0% vs. 2.7%). Nausea was reported as the primary reason for drug discontinuation in approximately 8.9% of bremelanotide patients. The manufacturer recommends taking the injection at least 45 minutes before sexual activity partly to allow the peak nausea period to pass before the sexual event.

Transient increases in blood pressure averaging 1 to 3 mmHg systolic were observed during the first 12 hours after injection. The label therefore contraindicates use in patients with known cardiovascular disease and advises caution in patients with hypertension or at elevated cardiovascular risk.

ACOG's clinical guidance on HSDD notes that "pharmacologic therapy should be considered in the context of a comprehensive approach that addresses psychological, relational, and biological factors." That framing is consistent with both the RECONNECT data and the way most Massachusetts prescribers integrate Vyleesi into practice: as one component of treatment, not as the only intervention.

Side Effects, Storage, and Practical Administration Notes for Massachusetts Patients

Bremelanotide comes as a single-use auto-injector containing 1.75 mg in 0.4 mL solution. Patients inject into the abdomen or thigh. The device does not require reconstitution; it is ready to use as supplied.

Storage requirements: refrigerate at 36°F to 46°F (2°C to 8°C) and protect from light. The injector may be kept at room temperature for up to 30 days if kept below 77°F (25°C). Massachusetts summers can push indoor temperatures above that threshold without air conditioning, so patients should be counseled about storage during warm months.

The injection is not intended for daily use. The label specifies no more than one dose per 24 hours. Using the drug more frequently than approximately eight times per month has not been studied for safety in controlled trials.

For patients who experience significant nausea, the label suggests that anti-nausea medications may be considered. Some prescribers in Massachusetts co-prescribe ondansetron 4 mg taken orally 30 minutes before the bremelanotide injection for patients who report nausea as a barrier to continued use.

How Massachusetts Prescribers Are Integrating Vyleesi Into Practice

Most Massachusetts gynecologists, sexual medicine specialists, and psychiatrists who treat HSDD approach bremelanotide prescribing through a structured intake. That intake includes a validated screening tool such as the Female Sexual Function Index (FSFI) or the Decreased Sexual Desire Screener (DSDS), a medication review to rule out desire-suppressing agents (particularly SSRIs and hormonal contraceptives with androgenic suppression), and a blood pressure check.

The DSM-5 diagnostic criteria for HSDD require that low desire cause marked distress or interpersonal difficulty, persist for at least six months, and not be better explained by another mental disorder or medical condition. Documenting those criteria in the chart is not just good clinical practice. It is the foundation of a successful insurance prior authorization and, if needed, an appeal.

Prescribers who see patients via telehealth in Massachusetts typically send the prescription electronically to a Massachusetts-licensed retail pharmacy for brand Vyleesi or to a licensed 503A compounding pharmacy for the compounded version. Some telehealth platforms handle all dispensing in-house through a pharmacy affiliate, in which case the patient receives the medication by mail.

What Massachusetts Patients Should Ask Their Prescriber Before Starting Vyleesi

A productive first conversation with a prescriber about bremelanotide should cover at least five specific topics. What is my baseline blood pressure, and does it exclude me from using this drug? Is my insurance likely to require a PA, and will your office submit it? Should I try the brand or compounded version first, given my cost situation? What should I do if nausea is severe? And how will we know after two to three months whether the drug is working?

The last question matters because RECONNECT tracked outcomes over 24 weeks. Response in clinical practice is typically assessed at 8 to 12 weeks. If the number of satisfying sexual events has not increased and desire scores have not improved by that checkpoint, continuing the drug at $1,200 per month (or even $140 per month) needs to be weighed against switching to an alternative approach.

The FDA label does not specify a minimum trial duration before discontinuation, but the RECONNECT protocol used 24 weeks as the primary endpoint window. Prescribers in Massachusetts who follow a structured 12-week re-evaluation cycle are generally aligned with that evidence base while minimizing unnecessary expenditure for patients who are not responding.